5:18 PM
 | 
May 16, 2014
 |  BC Extra  |  Company News

Pfizer planning palbociclib submission

Pfizer Inc. (NYSE:PFE) said it plans to submit an NDA to FDA early next quarter for palbociclib in combination with Femara letrozole from Novartis AG (NYSE:NVS; SIX:NOVN) as first-line treatment of...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >